Optimizing Bridging Therapies and Post–CAR T Approaches

Author(s):

Kristen M. O’Dwyer, MD ,Aaron Logan, MD, PhD

Panelists discuss the impact of blinatumomab’s FDA approval on sequencing chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory acute lymphoblastic leukemia (R/R ALL), the use of bridging therapies prior to CAR T infusion, and approaches to consolidation or maintenance treatment following CAR T therapy.

EP: 1.Introduction to CAR T-Cell Therapies in R/R ALL

EP: 2.Clinical Trials and Real-World Data on Brexu-Cel

EP: 3.Obe-Cel and MRD Outcomes: Insights and Comparisons

EP: 4.Shifting Treatment Paradigms in R/R ALL

Now Viewing

EP: 5.Optimizing Bridging Therapies and Post–CAR T Approaches

EP: 6.Addressing Toxicities in CAR T-Cell Therapy

EP: 7.Health Care Resource Utilization and Transition of Care

EP: 8.Outpatient CAR T Therapy and Expanding Access

EP: 9.Reflections and Future Directions in R/R ALL

Video content above is prompted by the following:

Dr. O’Dwyer to Dr. Molina: With blinatumomab’s FDA approval in the earlier-line setting in ALL, does this impact how you sequence CAR-T cell therapy for your R/R ALL patients?
Dr. O’Dwyer to Dr. Shaughnessy: In real-life day-to-day practice, how often are you utilizing bridging therapy prior to CAR T cells, and what agents are you typically using? What is the role of bridging therapies prior to CAR T cells being infused?
Resource link: Park JH et al. Bridging therapies FELIX study. ASH 2024 poster abstract or see Appendix 6
Dr. O’Dwyer to Dr. Logan (then open to panelists): What is your consolidation or maintenance treatment approach post CAR T-cell therapy? Can CAR T-cell therapy be a stand-alone therapy?

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!